Are the results of pancreatectomy for pancreatic cancer improving?

Gregory G. Tsiotos, Michael B. Farnell, Michael G. Sarr

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Although pancreatectomy is still performed in a few patients with pancreatic cancer, and nearly all patients who develop pancreatic cancer eventually die of their disease, significant improvements have been made recently. Pancreatectomy is now safer, with major morbidity (hemorrhage, pancreatic anastomotic leak, intraabdominal sepsis) occurring in only about 20% and operative mortality of less than 5%. Two (seemingly subtle) issues cannot be overemphasized when someone carefully studies the literature: (1) There is a crucial difference between actuarial and actual survival, with the former generally being higher whereas the latter is true; and (2) careful re- review of pathologic specimens (especially in long-term survivors) initially diagnosed as pancreatic cancer, preferably by an independent pathologist before publishing long-term results is essential. (Erroneous inclusion of patients with nonductal carcinoma substantially and artificially increases survival.) After curative resection, 5-year actual survival is realistically about 10% with median survivals of 12 to 18 months. Ill certain subgroups with favorable pathologic characteristics (neoplasms < 2 cm without nodal or perineural invasion) the prognosis appears to be significantly better, with the 5-year survival about 20%. The recent improvements in postoperative morbidity and mortality and long-term outcome (resulting also in decreased cost of care of such patients) have occurred typically in centers with an invested interest in and proven record with pancreatic surgery. Further improvements in survival should be sought at the areas of earlier diagnosis and novel treatments designed to prevent locoregional recurrences; the role of extended resections must be determined by prospective, randomized trials.

Original languageEnglish (US)
Pages (from-to)913-919
Number of pages7
JournalWorld Journal of Surgery
Volume23
Issue number9
DOIs
StatePublished - Sep 1999

Fingerprint

Pancreatectomy
Pancreatic Neoplasms
Survival
Morbidity
Anastomotic Leak
Mortality
Survivors
Early Diagnosis
Sepsis
Patient Care
Hemorrhage
Carcinoma
Costs and Cost Analysis
Recurrence
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Are the results of pancreatectomy for pancreatic cancer improving? / Tsiotos, Gregory G.; Farnell, Michael B.; Sarr, Michael G.

In: World Journal of Surgery, Vol. 23, No. 9, 09.1999, p. 913-919.

Research output: Contribution to journalArticle

Tsiotos, Gregory G. ; Farnell, Michael B. ; Sarr, Michael G. / Are the results of pancreatectomy for pancreatic cancer improving?. In: World Journal of Surgery. 1999 ; Vol. 23, No. 9. pp. 913-919.
@article{d4070c17aec640cea256b24475521746,
title = "Are the results of pancreatectomy for pancreatic cancer improving?",
abstract = "Although pancreatectomy is still performed in a few patients with pancreatic cancer, and nearly all patients who develop pancreatic cancer eventually die of their disease, significant improvements have been made recently. Pancreatectomy is now safer, with major morbidity (hemorrhage, pancreatic anastomotic leak, intraabdominal sepsis) occurring in only about 20{\%} and operative mortality of less than 5{\%}. Two (seemingly subtle) issues cannot be overemphasized when someone carefully studies the literature: (1) There is a crucial difference between actuarial and actual survival, with the former generally being higher whereas the latter is true; and (2) careful re- review of pathologic specimens (especially in long-term survivors) initially diagnosed as pancreatic cancer, preferably by an independent pathologist before publishing long-term results is essential. (Erroneous inclusion of patients with nonductal carcinoma substantially and artificially increases survival.) After curative resection, 5-year actual survival is realistically about 10{\%} with median survivals of 12 to 18 months. Ill certain subgroups with favorable pathologic characteristics (neoplasms < 2 cm without nodal or perineural invasion) the prognosis appears to be significantly better, with the 5-year survival about 20{\%}. The recent improvements in postoperative morbidity and mortality and long-term outcome (resulting also in decreased cost of care of such patients) have occurred typically in centers with an invested interest in and proven record with pancreatic surgery. Further improvements in survival should be sought at the areas of earlier diagnosis and novel treatments designed to prevent locoregional recurrences; the role of extended resections must be determined by prospective, randomized trials.",
author = "Tsiotos, {Gregory G.} and Farnell, {Michael B.} and Sarr, {Michael G.}",
year = "1999",
month = "9",
doi = "10.1007/s002689900599",
language = "English (US)",
volume = "23",
pages = "913--919",
journal = "Presentations from the 9th Annual Electric Utilities Environmental Conference",
issn = "0364-2313",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Are the results of pancreatectomy for pancreatic cancer improving?

AU - Tsiotos, Gregory G.

AU - Farnell, Michael B.

AU - Sarr, Michael G.

PY - 1999/9

Y1 - 1999/9

N2 - Although pancreatectomy is still performed in a few patients with pancreatic cancer, and nearly all patients who develop pancreatic cancer eventually die of their disease, significant improvements have been made recently. Pancreatectomy is now safer, with major morbidity (hemorrhage, pancreatic anastomotic leak, intraabdominal sepsis) occurring in only about 20% and operative mortality of less than 5%. Two (seemingly subtle) issues cannot be overemphasized when someone carefully studies the literature: (1) There is a crucial difference between actuarial and actual survival, with the former generally being higher whereas the latter is true; and (2) careful re- review of pathologic specimens (especially in long-term survivors) initially diagnosed as pancreatic cancer, preferably by an independent pathologist before publishing long-term results is essential. (Erroneous inclusion of patients with nonductal carcinoma substantially and artificially increases survival.) After curative resection, 5-year actual survival is realistically about 10% with median survivals of 12 to 18 months. Ill certain subgroups with favorable pathologic characteristics (neoplasms < 2 cm without nodal or perineural invasion) the prognosis appears to be significantly better, with the 5-year survival about 20%. The recent improvements in postoperative morbidity and mortality and long-term outcome (resulting also in decreased cost of care of such patients) have occurred typically in centers with an invested interest in and proven record with pancreatic surgery. Further improvements in survival should be sought at the areas of earlier diagnosis and novel treatments designed to prevent locoregional recurrences; the role of extended resections must be determined by prospective, randomized trials.

AB - Although pancreatectomy is still performed in a few patients with pancreatic cancer, and nearly all patients who develop pancreatic cancer eventually die of their disease, significant improvements have been made recently. Pancreatectomy is now safer, with major morbidity (hemorrhage, pancreatic anastomotic leak, intraabdominal sepsis) occurring in only about 20% and operative mortality of less than 5%. Two (seemingly subtle) issues cannot be overemphasized when someone carefully studies the literature: (1) There is a crucial difference between actuarial and actual survival, with the former generally being higher whereas the latter is true; and (2) careful re- review of pathologic specimens (especially in long-term survivors) initially diagnosed as pancreatic cancer, preferably by an independent pathologist before publishing long-term results is essential. (Erroneous inclusion of patients with nonductal carcinoma substantially and artificially increases survival.) After curative resection, 5-year actual survival is realistically about 10% with median survivals of 12 to 18 months. Ill certain subgroups with favorable pathologic characteristics (neoplasms < 2 cm without nodal or perineural invasion) the prognosis appears to be significantly better, with the 5-year survival about 20%. The recent improvements in postoperative morbidity and mortality and long-term outcome (resulting also in decreased cost of care of such patients) have occurred typically in centers with an invested interest in and proven record with pancreatic surgery. Further improvements in survival should be sought at the areas of earlier diagnosis and novel treatments designed to prevent locoregional recurrences; the role of extended resections must be determined by prospective, randomized trials.

UR - http://www.scopus.com/inward/record.url?scp=0032791547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032791547&partnerID=8YFLogxK

U2 - 10.1007/s002689900599

DO - 10.1007/s002689900599

M3 - Article

C2 - 10449820

AN - SCOPUS:0032791547

VL - 23

SP - 913

EP - 919

JO - Presentations from the 9th Annual Electric Utilities Environmental Conference

JF - Presentations from the 9th Annual Electric Utilities Environmental Conference

SN - 0364-2313

IS - 9

ER -